{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Differentiation&page=13", "query": { "condition": "Differentiation", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 406, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Differentiation&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Differentiation&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T22:40:43.148Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00984074", "title": "MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "blood-oxygen-level-dependent functional magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "diffusion tensor imaging", "type": "PROCEDURE" }, { "name": "dynamic contrast-enhanced magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "functional magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "radiation therapy treatment planning/simulation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 3, "start_date": "2008-10", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2019-04-24", "last_synced_at": "2026-10-26T22:40:43.148Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00984074" }, { "nct_id": "NCT02193724", "title": "Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Retinoblastoma" ], "interventions": [ { "name": "Skin Biopsy", "type": "OTHER" }, { "name": "Blood Draw", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 15, "start_date": "2014-11-04", "completion_date": "2019-08-23", "has_results": false, "last_update_posted_date": "2020-10-23", "last_synced_at": "2026-10-26T22:40:43.148Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02193724" }, { "nct_id": "NCT00268229", "title": "Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "imatinib mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2003-07", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2013-02-15", "last_synced_at": "2026-10-26T22:40:43.148Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00268229" }, { "nct_id": "NCT00064025", "title": "Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Adenosquamous Carcinoma", "Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation", "Recurrent Uterine Corpus Carcinoma", "Stage I Uterine Corpus Cancer", "Stage II Uterine Corpus Cancer", "Stage III Uterine Corpus Cancer", "Stage IV Uterine Corpus Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Medroxyprogesterone", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "DRUG", "PROCEDURE" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 75, "start_date": "2004-04", "completion_date": null, "has_results": true, "last_update_posted_date": "2016-04-11", "last_synced_at": "2026-10-26T22:40:43.148Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00064025" }, { "nct_id": "NCT03434262", "title": "SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Ependymoma", "Anaplastic Ganglioglioma", "Anaplastic Meningioma", "Anaplastic Oligodendroglioma", "Pleomorphic Xanthoastrocytoma, Anaplastic", "Atypical Teratoid/Rhabdoid Tumor", "Brain Cancer", "Brain Tumor", "Central Nervous System Neoplasms", "Choroid Plexus Carcinoma", "CNS Embryonal Tumor With Rhabdoid Features", "Ganglioneuroblastoma of Central Nervous System", "CNS Tumor", "Embryonal Tumor of CNS", "Ependymoma", "Glioblastoma", "Glioma", "Glioma, Malignant", "Medulloblastoma", "Medulloblastoma; Unspecified Site", "Medulloepithelioma", "Neuroepithelial Tumor", "Neoplasms", "Neoplasms, Neuroepithelial", "Papillary Tumor of the Pineal Region (High-grade Only)", "Pediatric Brain Tumor", "Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)", "Pineoblastoma", "Primitive Neuroectodermal Tumor", "Recurrent Medulloblastoma", "Refractory Brain Tumor", "Neuroblastoma. CNS", "Glioblastoma, IDH-mutant", "Glioblastoma, IDH-wildtype", "Medulloblastoma, Group 3", "Medulloblastoma, Group 4", "Glioma, High Grade", "Neuroepithelial Tumor, High Grade", "Medulloblastoma, SHH-activated and TP53 Mutant", "Medulloblastoma, SHH-activated and TP53 Wildtype", "Medulloblastoma, Chromosome 9q Loss", "Medulloblastoma, Non-WNT Non-SHH, NOS", "Medulloblastoma, Non-WNT/Non-SHH", "Medulloblastoma, PTCH1 Mutation", "Medulloblastoma, WNT-activated", "Ependymoma, Recurrent", "Glioma, Recurrent High Grade", "Glioma, Recurrent Malignant", "Embryonal Tumor, NOS", "Glioma, Diffuse Midline, H3K27M-mutant", "Embryonal Tumor With Multilayered Rosettes (ETMR)", "Ependymoma, NOS, WHO Grade III", "Ependymoma, NOS, WHO Grade II", "Medulloblastoma, G3/G4", "Ependymoma, RELA Fusion Positive" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "ribociclib", "type": "DRUG" }, { "name": "sonidegib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "39 Years", "sex": "ALL", "summary": "1 Year to 39 Years" }, "enrollment_count": 68, "start_date": "2018-03-05", "completion_date": "2024-05-24", "has_results": false, "last_update_posted_date": "2024-05-31", "last_synced_at": "2026-10-26T22:40:43.148Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03434262" }, { "nct_id": "NCT00784303", "title": "Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Cancer" ], "interventions": [ { "name": "Lenvatinib (DTC Cohort)", "type": "DRUG" }, { "name": "Lenvatinib (MTC Cohort)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 117, "start_date": "2008-11-06", "completion_date": "2019-03-29", "has_results": true, "last_update_posted_date": "2020-04-22", "last_synced_at": "2026-10-26T22:40:43.148Z", "location_count": 23, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Los Gatos, California + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Gatos", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00784303" }, { "nct_id": "NCT01219361", "title": "Evaluation of Donated Human Embryos Following in Vitro Fertilization", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Validation of Laboratory Techniques", "Validation of Laboratory Methods", "Assessment of Laboratory Staff Proficiency" ], "interventions": [], "intervention_types": [], "sponsor": "Reproductive Medicine Associates of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 5000, "start_date": "2005-07", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-02-07", "last_synced_at": "2026-10-26T22:40:43.148Z", "location_count": 1, "location_summary": "Basking Ridge, New Jersey", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01219361" }, { "nct_id": "NCT03744793", "title": "Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant", "Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation", "Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation", "Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant", "Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant", "Metastatic Urothelial Carcinoma", "MTAP Negative" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-04-11", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-26T22:40:43.148Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03744793" }, { "nct_id": "NCT03912818", "title": "Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Adenocarcinoma", "Bladder Mixed Adenocarcinoma", "Bladder Squamous Cell Carcinoma", "Bladder Urothelial Carcinoma", "Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant", "Infiltrating Bladder Urothelial Carcinoma With Giant Cells", "Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation", "Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation", "Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant", "Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant", "Infiltrating Bladder Urothelial Carcinoma, Nested Variant", "Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cystectomy", "type": "PROCEDURE" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2019-04-10", "completion_date": "2022-08-11", "has_results": true, "last_update_posted_date": "2023-09-11", "last_synced_at": "2026-10-26T22:40:43.148Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03912818" }, { "nct_id": "NCT00383474", "title": "Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia", "Adult Acute Monoblastic Leukemia", "Adult Acute Monocytic Leukemia", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With Maturation", "Adult Acute Myeloid Leukemia With Minimal Differentiation", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL", "Adult Acute Myeloid Leukemia Without Maturation", "Adult Acute Myelomonocytic Leukemia", "Adult Erythroleukemia", "Adult Pure Erythroid Leukemia", "Blastic Phase", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Disease", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Tipifarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2006-08", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2015-04-15", "last_synced_at": "2026-10-26T22:40:43.148Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00383474" } ] }